glenn robertelli

Glenn Robertelli, CEO of RI Bio, has over 25 years of international experience in the technology, medical, and consumer products industries. Before joining RI BIo, he served as the co-founder and Chief Operating Officer (COO) at Admetsys and has been instrumental in driving the convergence of biosensors, Artificial Intelligence, patient-specific metabolic modeling and automated drug delivery. Under his leadership, Admetsys developed a real-time diagnostics and clinical robotics platform using artificial intelligence and biosensors to optimize patient outcomes. This platform, often referred to as an artificial pancreas or Automated Insulin Delivery System, reads blood analytes in real-time, creates patient-specific metabolic models, and manages patient glucose levels automatically. The system has been approved in Europe and successfully completed three FDA clinical trials in the USA under Breakthrough Device Designation. Robertelli’s extensive expertise is recognized globally, having been named Entrepreneur of the Year by Entrepreneur Magazine and listed among the Top 10 Global Entrepreneurs by AskMen’s Magazine. He holds a patent for a System and Method for Clinical Quality and Safety Automation and has a proven track record in business strategy, innovation, and entrepreneurship. Before Admetsys, Robertelli was the founder and CEO of Intelligen LLC and Intelligen (Asia-Pacific) Ltd, where he led the development of ViewGuard® and GearGuard® products, now embedded in millions of mobile devices worldwide. He also graduated from Johnson & Johnson’s Leadership Development Program and worked extensively inside and outside the USA in roles including operations, supply chain, strategic marketing, M&A, and new product development.